Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.

Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM.

J Lipid Res. 2013 Feb;54(2):467-72. doi: 10.1194/jlr.M032615. Epub 2012 Nov 19.

2.

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators.

J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

PMID:
25670362
3.

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Shinkai H.

Vasc Health Risk Manag. 2012;8:323-31. doi: 10.2147/VHRM.S25238. Epub 2012 May 15. Review.

4.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
5.

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM.

J Clin Lipidol. 2015 Jan-Feb;9(1):93-102. doi: 10.1016/j.jacl.2014.09.013. Epub 2014 Oct 13.

6.

Anacetrapib, a cholesteryl ester transfer protein inhibitor.

Hooper AJ, Burnett JR.

Expert Opin Investig Drugs. 2012 Jan;21(1):103-9. doi: 10.1517/13543784.2012.642499. Epub 2011 Dec 22.

PMID:
22191425
7.

Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.

Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):543-9. doi: 10.1177/1074248414529621. Epub 2014 Apr 14.

PMID:
24737712
8.

Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

Page MM, Hooper AJ, Burnett JR.

Expert Opin Pharmacother. 2016;17(2):275-81. doi: 10.1517/14656566.2016.1129402. Epub 2015 Dec 28. Review.

PMID:
26642232
9.

Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.

Masson D.

Curr Opin Investig Drugs. 2009 Sep;10(9):980-7. Review.

PMID:
19705341
10.

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA.

Lancet. 2007 Dec 8;370(9603):1907-14.

PMID:
18068514
11.

Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Mohammadpour AH, Akhlaghi F.

Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.

12.

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.

van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y.

J Lipid Res. 2015 Nov;56(11):2085-93. doi: 10.1194/jlr.M057794. Epub 2015 Sep 4.

13.

Anacetrapib: hope for CETP inhibitors?

Gurfinkel R, Joy TR.

Cardiovasc Ther. 2011 Oct;29(5):327-39. doi: 10.1111/j.1755-5922.2010.00142.x. Epub 2010 Apr 9. Review.

PMID:
20406242
14.

Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.

Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, Donnelly M, Gai C, Gewain A, Lederman H, Jensen KK, Ai X, Vachal P, Akinsanya KO, Cleary MA, Previs SF, Dansky HM, Johns DG.

Eur J Pharmacol. 2014 Oct 5;740:410-6. doi: 10.1016/j.ejphar.2014.04.015. Epub 2014 Apr 21.

PMID:
24769414
15.

Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.

Mabuchi H, Nohara A, Inazu A.

Mol Cells. 2014 Nov;37(11):777-84. doi: 10.14348/molcells.2014.0265. Epub 2014 Nov 6. Review.

16.

Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.

Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP.

Eur J Pharmacol. 2015 Sep 5;762:256-62. doi: 10.1016/j.ejphar.2015.05.061. Epub 2015 Jun 3.

PMID:
26049012
17.

Anacetrapib: a new weapon against dyslipidemia.

Aperis G, Paliouras C, Tsampikaki E, Papakonstantinou N, Alivanis P.

Curr Clin Pharmacol. 2011 Nov;6(4):227-35. Review.

PMID:
22082322
18.
19.

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, Wagner JA, Luk JM, Johnson-Levonas AO, Anderson MS, Dansky HM.

J Lipid Res. 2012 Mar;53(3):540-7. doi: 10.1194/jlr.M018010. Epub 2011 Dec 17.

20.

Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.

Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.

Eur J Pharmacol. 2014 Oct 5;740:135-43. doi: 10.1016/j.ejphar.2014.06.022. Epub 2014 Jul 5.

PMID:
25008069

Supplemental Content

Support Center